Significados de myelodysplastic syndromes en inglés

Acute myeloid leukemia and myelodysplastic syndromes represented the most common disease indications.

Objective: Unbalanced chromosomal aberrations are common in myelodysplastic syndromes and have prognostic implications.

All patients belonged to the more aggressive subtypes of myelodysplastic syndromes.

The relationship between these cytopenias and myeloid neoplasms like myelodysplastic syndromes is currently poorly defined.

Results: Many rare germline mutations have been identified that lead to acute leukemia and myelodysplastic syndromes.

The other subset has cytogenetic abnormalities similar to those in myelodysplastic syndromes and a poor prognosis.

Selecting the most appropriate treatment for patients with myelodysplastic syndromes (MDS) requires careful consideration of several factors.

Some of these factors have been studied and used in chemotherapy-induced neutropenia, myelodysplastic syndromes, and bone marrow failure syndromes.

Some drugs can home in on these changes however -notably drugs used to treat myelodysplastic syndromes, sometimes known as pre-leukemia.

The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis.

In patients with myelodysplastic syndromes and symptomatic anemia, we evaluated the safety and hematologic activity of lenalidomide, a novel analogue of thalidomide.

Celgene will acquire Vidaza, approved in the United States for myelodysplastic syndromes, a group of blood disorders that can lead to leukemia.

The myelodysplastic syndromes (MDS) are heterogeneous clonal disorders of ineffective hematopoiesis characterized by limited treatment options and a poor prognosis.

DNA flow cytometric analysis of unfixed bone marrow cells stained with propidium iodide was carried out in 33 patients with untreated primary myelodysplastic syndromes.

In congenital neutropenia, the inherent risk of developing myelodysplastic syndromes or AML requires careful monitoring, including routine blood counts and annual bone marrow examinations.

Cyclacel is now focusing its clinical development priorities on sapacitabine in acute myeloid leukemia in the elderly, in myelodysplastic syndromes and in cutaneous T-cell lymphoma.